Form 4: TransMedics Group Director Edward M. Basile Reports Acquisition of Stock Options and Restricted Stock Units

Director Edward M. Basile reported the acquisition of 732 restricted stock units and 1,154 stock options in TransMedics Group, Inc. on May 23, 2024.

Summary

• On May 23, 2024, Edward M. Basile, a director of TransMedics Group, Inc., acquired 732 restricted stock units (RSUs) and 1,154 stock options.
• The RSUs represent a contingent right to receive one share of TransMedics Group's common stock each.
• The stock options have an exercise price of $137.53 and vest fully on the earlier of May 23, 2025, or the date of the 2025 annual meeting of stockholders, contingent upon continued service.
• Following these transactions, Basile directly owns 1,925 shares of common stock and 1,154 stock options.

Sentiment

Score: 6

Explanation: The sentiment is neutral. It's a routine disclosure of stock options and RSUs granted to a director. It doesn't inherently indicate positive or negative sentiment, but rather reflects standard compensation practices.

Positives

• The acquisition of stock options and restricted stock units by a director could be seen as a positive sign, indicating confidence in the company's future performance.

Industry Context

Form 4 filings are routine disclosures required by the SEC to provide transparency into the transactions of company insiders. These filings are closely watched by investors to gauge sentiment and potential future actions of key personnel.

Comparison to Industry Standards

• Comparing the vesting schedule and option terms to those of similar companies in the medical device industry would provide context on whether these terms are standard or particularly favorable.
• For example, companies like Medtronic or Boston Scientific often grant stock options and RSUs to their executives and directors as part of their compensation packages, with vesting schedules typically ranging from three to five years.

Stakeholder Impact

• The acquisition of shares and options by a director can signal confidence to shareholders.
• The vesting of options contingent on continued service can incentivize the director to remain with the company.

Key Dates